New drug aims to shrink swollen glands in rare disease

NCT ID NCT07025330

Ongoing Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 24, 2026 · Updated 4 times

Summary

This study tests whether efgartigimod, a drug that lowers certain antibodies, can reduce swelling in the tear glands, saliva glands, or pancreas of people with IgG4-related disease. Five adults will receive weekly injections for 12 weeks and have regular scans and checkups. The goal is to see if the drug can control the disease and improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: efgartigimod (a drug that lowers certain antibodies)
What this could lead to: If it works, this could point toward a new treatment option for IgG4-related disease, reducing gland swelling and inflammation.
What could go wrong: This is a very small, early-phase trial with only 5 participants, so results may not apply to everyone. The drug may not reduce swelling or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGG4-RELATED DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGG4-RELATED DISEASE

Contacts and locations

Locations

Stanford University

Palo Alto, California, 94304-2210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.